Editing Paroxetine (section)

==Research==
Several studies have suggested that paroxetine can be used in the treatment of [[premature ejaculation]]. In particular, intravaginal ejaculation latency time (IELT) was found to increase 6- to 13-fold, which was somewhat longer than the delay achieved by the treatment with other SSRIs (fluvoxamine, fluoxetine, sertraline, and citalopram).<ref name="pmid9690692">{{cite journal | vauthors = Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B | title = Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline | journal = Journal of Clinical Psychopharmacology | volume = 18 | issue = 4 | pages = 274–281 | date = August 1998 | pmid = 9690692 | doi = 10.1097/00004714-199808000-00004 }}</ref><ref name="pmid11763001">{{cite journal | vauthors = Waldinger MD, Zwinderman AH, Olivier B | title = SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram | journal = Journal of Clinical Psychopharmacology | volume = 21 | issue = 6 | pages = 556–560 | date = December 2001 | pmid = 11763001 | doi = 10.1097/00004714-200112000-00003 | s2cid = 36888042 }}</ref><ref name="pmid15363569">{{cite journal | vauthors = Waldinger MD, Zwinderman AH, Olivier B | title = On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment | journal = European Urology | volume = 46 | issue = 4 | pages = 510–5; discussion 516 | date = October 2004 | pmid = 15363569 | doi = 10.1016/j.eururo.2004.05.005 }}</ref> However, paroxetine taken acutely ("on demand") 3–10 hours before coitus resulted only in a "clinically irrelevant and sexually unsatisfactory" 1.5-fold delay of ejaculation and was inferior to [[clomipramine]], which induced a fourfold delay.<ref name="pmid15363569"/>

There is also evidence that paroxetine may be effective in the treatment of [[compulsive gambling]]<ref>{{cite journal | vauthors = Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R | title = A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling | journal = The Journal of Clinical Psychiatry | volume = 63 | issue = 6 | pages = 501–507 | date = June 2002 | pmid = 12088161 | doi = 10.4088/JCP.v63n0606 }}</ref> and [[hot flashes]].<ref>{{cite journal | vauthors = Weitzner MA, Moncello J, Jacobsen PB, Minton S | title = A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer | journal = Journal of Pain and Symptom Management | volume = 23 | issue = 4 | pages = 337–345 | date = April 2002 | pmid = 11997203 | doi = 10.1016/S0885-3924(02)00379-2 | doi-access = free }}</ref>

Benefits of paroxetine prescription for [[diabetic neuropathy]]<ref>{{cite journal | vauthors = Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF | title = The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms | journal = Pain | volume = 42 | issue = 2 | pages = 135–144 | date = August 1990 | pmid = 2147235 | doi = 10.1016/0304-3959(90)91157-E | s2cid = 42327989 }}</ref> or chronic [[tension headache]]<ref name="pmid8132436">{{cite journal | vauthors = Langemark M, Olesen J | title = Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial | journal = Headache | volume = 34 | issue = 1 | pages = 20–24 | date = January 1994 | pmid = 8132436 | doi = 10.1111/j.1526-4610.1994.hed3401020.x | s2cid = 13715774 }}</ref> are uncertain.

Although the evidence is conflicting, paroxetine may be effective for the treatment of [[dysthymia]], a chronic disorder involving depressive symptoms for most days of the year.<ref name="pmid19017592">{{cite journal | vauthors = Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN | title = Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians | journal = Annals of Internal Medicine | volume = 149 | issue = 10 | pages = 734–750 | date = November 2008 | pmid = 19017592 | doi = 10.7326/0003-4819-149-10-200811180-00008 | doi-access = free }}</ref>

There is evidence to support that paroxetine selectively binds to and inhibits [[G protein-coupled receptor kinase 2]] (GRK2) in mice with heart failure. Since GRK2 regulates the activity of the beta [[adrenergic receptor]], which becomes desensitized in cases of [[heart failure]], paroxetine (or a paroxetine derivative) could be used as a heart failure treatment in the future.<ref name=":0">{{cite journal | vauthors = Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, Cheung JY, Sklar LA, Koch WJ, Tesmer JJ | title = Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility | journal = ACS Chemical Biology | volume = 7 | issue = 11 | pages = 1830–1839 | date = November 2012 | pmid = 22882301 | pmc = 3500392 | doi = 10.1021/cb3003013 }}</ref><ref name=":1">{{cite journal | vauthors = Waldschmidt HV, Homan KT, Cato MC, Cruz-Rodríguez O, Cannavo A, Wilson MW, Song J, Cheung JY, Koch WJ, Tesmer JJ, Larsen SD | title = Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine | journal = Journal of Medicinal Chemistry | volume = 60 | issue = 7 | pages = 3052–3069 | date = April 2017 | pmid = 28323425 | pmc = 5641445 | doi = 10.1021/acs.jmedchem.7b00112 }}</ref><ref>{{Cite web |title=Common antidepressant may hold key to heart failure reversal |url=https://www.sciencedaily.com/releases/2015/03/150304152607.htm |access-date=19 April 2022 |website=ScienceDaily |archive-date=5 April 2019 |archive-url=https://web.archive.org/web/20190405032837/https://www.sciencedaily.com/releases/2015/03/150304152607.htm |url-status=live }}</ref>

Paroxetine has been identified as a potential [[disease-modifying osteoarthritis drug]].<ref>{{cite journal | vauthors = Carlson EL, Karuppagounder V, Pinamont WJ, Yoshioka NK, Ahmad A, Schott EM, Le Bleu HK, Zuscik MJ, Elbarbary RA, Kamal F | title = Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis | journal = Science Translational Medicine | volume = 13 | issue = 580 | pages = eaau8491 | date = February 2021 | pmid = 33568523 | doi = 10.1126/scitranslmed.aau8491 | s2cid = 231875553 }}</ref>